Results come after positive results from a trial among people with idiopathic pulmomary disease.

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural ...

New study details gaps between actual and recommended use of statins and other lipid-lowering drugs—and estimates public ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...